BIONEER Corporation
- 8월 9일
- 2분 분량
최종 수정일: 7일 전
CEO: Han Oh Park
Person in Charge: Min Jung
Tel.: +82-42-939-6460
Email: min.jung@bioneer.co.kr / global@bioneer.co.kr
Website: https://bioneer.com/
Address: Bioneer Global Center, 71, Techno 2-ro, Yuseong-gu, Daejeon 34013, Republic of Korea
Main Products: Molecular diagnostics and life-science systems
Company Introduction
(R&D 46%)
(USA, Germany, Indonesia, China) | Driven by the spirit of Bio-Pioneers and Bio-Engineers, BIONEER is dedicated to empowering healthcare worldwide. We strive to lead the way in innovative disease prevention, diagnostics, and therapeutics, delivering meaningful advancements for human lives. Guided by scientific rationalism and societal values, we remain committed to providing top-tier solutions and partnering with global healthcare leaders for a healthier future. Business Pillars: Molecular Diagnostics, Life Science, Nano Bio, Cosmeceuticals, Probiotics, siRNA Therapeutics |
No. | Product Name | HS CODE |
1 | ExiStation™ 48 | 8479 89 9099, 9027 50 9000 |
2 | ExiStation™ FA 96 | 9027 89 1000 |
3 | IRON-qPCR™ | 9027 89 1000 |
Product Description
 | A WHO PQ-certified and Global Fund-listed modular MDx system. Utilizing pre-mixed, vacuum-dried reagents to eliminate manual pipetting errors, it features a 4-stage anti-contamination design and scalable modular expansion—delivering seamless sample-to-result testing in 2.5 to 3 hours. [Assay Portfolio] HIV (TFDA, WHO PQ), HBV, HCV (GF), Transplant, TB, MDR-TB, Respiratory, STI, HPV, Vector-borne, GI, Genotyping (CE-IVD)  |
 | A high-throughput, fully automated platform executing the entire workflow—from automated de/re-capping to qPCR—in a single unit. Its built-in self-decontamination system with HEPA/Ozone filters protects operators from aerosol risks, while its compact footprint (164×75 cm) yields 96 results in 2 hours (up to 576 tests/day). [Assay Portfolio] HIV, HBV, HCV Viral Load, Respiratory (CE-IVDR) Transplant, HPV/STI, Blood Bank (Pipeline)  |
 | An ultra-rapid POC system running up to 40 targets in 40 minutes. Featuring standalone, low-power operation for decentralized labs, its advanced TB/MDR/pre-XDR (RFIA) kit detects crucial rpoB mutations (I491F) missed by legacy systems, proven by a 100% QCMD EQA accuracy rate. [Assay Portfolio] TB/MDR/pre-XDR (TFDA, WHO PQ Trial, CE-IVD), Respiratory (CE-IVDR), HIV, STI-12, AMR, GI (Pipeline)  |
댓글